(BRK.A), (BRK.B)
Commercial drug product manufacturing will be added at the Lubrizol’s Particle Sciences facility in Bethlehem, Pennsylvania.
The move to become a commercial drug product manufacturer, rather than just a producer of trial supplies used in testing, will enable Particle Science to produce pharmaceutical products for commercial sale by its customers.
Particle Science already has several customers lined up for its new service, and plans to hire an additional 30 employees to its existing workforce of 85 employees.
The roughly $10 million expansion of its facility will be adjacent to the existing development and clinical trial manufacturing site, offering customers a seamless flow from development through manufacturing.
The new space, which is expected to be operational in the fourth quarter of 2017, will accommodate both sterile and non-sterile products, highly potent compounds, and organic solvent processing.
The expansion id part of Lubrizol’s $60 million investment that will focus on new product solutions, capacity expansion and additional cGMP manufacturing.
© 2017 David Mazor
Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.